The COVID-19 infection is associated with dyslipidemia and cardiovascular complications. The aim of the study was to determine the content of ApoA1, ApoB, and oxidized low-density lipoproteins (oxLDL) in the plasma of patients (
n
= 81) with COVID-19, diabetes, and cardiovascular disease (CVD). ApoA1, ApoB, and oxLDL were determined using enzyme-linked immunosorbent assay kits (Elabscience, United States). The measurements were performed at an optical wavelength of 450 nm. It was shown that the level of ApoA1 in the blood of patients with type 2 diabetes and especially with COVID-19 was significantly lower than in the blood of healthy people. Blood ApoA1 levels did not show a further decrease in patients with both COVID-19 and diabetes or CVD compared to patients with COVID-19 without concomitant diseases. It was found that the level of ApoB in the blood of patients with diabetes and, especially, with COVID-19 is significantly higher than in the blood of healthy people. Blood levels of ApoB and oxLDL are higher in patients with both COVID-19 and diabetes or CVD compared to patients with COVID-19 without comorbidities. Thus, levels of ApoA1, ApoB, and oxLDL may be promising markers of COVID-19.
To study the main ways of progression and mutual complication of vascular pathology in patients with type 1 diabetes mellitus with type 2 diabetes in order to improve modern methods of prevention and treatment» (State registration number: 0116U002163). Institution, which financed the research: National Academy of Medical Sciences of Ukraine. The authors assume responsibility for the published work. The authors guarantee absence of competing interests and their own financial interest when carrying out the research and writing the article. The manuscript was received by the editorial staff 28.11.2018.
Increased levels of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (ApoA1) in plasma is associated with a reduced risk of developing cardiovascular diseases (CVD). In addition to its potential cardioprotective function, HDL and ApoA1, the main HDL apolipoprotein, also have antidiabetic properties. The aim of the study was to determine the level of ApoA1 in the blood of patients (n = 81) with type 2 diabetes mellitus and COVID-19. ApoA1 was determined by enzyme-linked immunosorbent assay (ELISA) (Elabscience, USA). The measurements were performed at an optical density of 450 nm. We showed that the level of ApoA1 in the blood of patients with type 2 diabetes and especially with COVID-19 was significantly lower than in the blood of healthy people. Blood ApoA1 levels did not show a further decrease in patients with both COVID-19 and diabetes compared with patients with COVID-19 without diabetes. Thus, the level of ApoA1 may be one of the promising markers of severe COVID-19.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.